Clinical and functional evaluation of intramyocardial implantation of autologous bone marrow cells treated with erythropoietinduring the CAD surgery (6-month results)

Aim. Clinical and functional evaluation of the implantation of autologous bone marrow cells treated with erythropoietin in laser channels during coronary bypass grafting in patients with end-stage coronary lesion.

Materials and methods. 60 patients with coronary artery disease with diffuse and (or) distal right coronary artery disease were randomized into two groups: patients of group 1 (n = 30) underwent coronary bypass grafting, implantation of autologous bone marrow cells treated with erythropoietin in laser channels, patients of the 2nd group (n = 30) were operated with coronary bypass grafting of the left coronary artery system. Assessment of the clinical status, myocardial perfusion and contractility was performed initially, 6 months after the operation.

Results. Six months after the operation, there was a more pronounced decrease in angina pectoris (CCS) in the main group compared to the control group, also we revealed a 6-minute walk test scores improvement. Based on two-stage scintigraphy (Tc99) in the main group before the surgical treatment, a rest perfusion defect was 8.5% [3.5, 18.5], a stress-induced perfusion defect – 7.0% [6.0, 12, 3]. In the control group, the rest defect was 9.1% [5.6, 12.4], the stress-induced perfusion defect was 7.3% [6.1, 8.7]. 6 months after surgery rest perfusion defect at the indirect revascularization group was 6.0% [2.5, 16.5] (p = 0.008), a stress-induced defect was 4.0% [1.5, 6.3] (p = 0.05). In the control group, the rest defect was 8.7% [5.3, 10.3], the stress-induced perfusion defect was 6.8% [5.3, 9.1] (p = 0.21). The results of scintigraphy with MIBG showed a left ventricle innervation defect (PID) significant decrease in the main group: initially 15.4% [14.2, 16.3], after 6 months 11.7% [9.3, 13, 2] (p = 0.045). In the control group, there was an unreliable decrease in PID: initially 14.3% [10.2, 17.3], after 6 months 13.8% [9.1, 14.2] (p = 0.14).

Conclusion. Our preliminary results revealed more pronounced effect of the new indirect revascularization method expressed as in myocardial perfusion improve, myocardial sympathetic innervation restoration and clinical status improvement in comparison with control group.

1. Ford ES, Ajani UA, Croft JB et al.Explanation of decrease in US deaths from coronary heart disease, 1980–2000. N Engl J Med. 2007; 356: 2388–2398.

2. Roger VL, Go AS, Lloyd­Jones DM et al. Heart disease and stroke statistics 2012 update: a report from the American Heart Association. Circulation. 2012; 124: e2–e220.

3. Мареев ВЮ, Фомин ИВ, Агеев ФТ, Беграмбекова ЮЛ, Васюк ЮА, Гарганеева АА и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (S6): 8–164. Mareev VYu, Fomin IV, Ageev FT, Begrambekova YuL, Vasyuk YuA, Garganeeva AA i dr. Klinicheskie rekomendacii OSSN – RKO – RNMOT. Serdechnaya nedostatochnost’: hronicheskaya (HSN) i ostraya dekompensirovannaya (ODSN). Diagnostika, profilaktika i lechenie. Kardiologiya. 2018; 58 (S6): 8–164.

4. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association. Circulation. 2011; 123: 933–944.

5. Бураковский ВИ. Сердечно-сосудистая хирургия. 1989: 752. Burakovsky VI. Cardiovascular Surgery. 1989: 752.

6. Effler DB. Acute coronary insufficiency (impending myocardial infarction and myocardial infarction): surgical treatment by the saphenous vein graft technique. Am J Cardiol. 1971 Nov; 28 (5): 598–607.

7. Бокерия ЛА. Минимально инвазивная хирургия сердца. М.: Медицина, 1998: 92. Bokeria LA. Minimally invasive surgery of the heart. M.: Medicine, 1998: 92.

8. Salomon NW, Page US, Bigelow JC et al. Reoperative coronary surgery. Comparative analysis of 6591 patients undergoing primary bypass and 508 patients undergoing reoperative coronary artery bypass. J Thorac Cardiovasc Surg. 1990; 100: 250–260.

9. Vincent J, Bardos P, Kruse J, Maass D. End stage coronary disease treated with the transmyocardial CO2 laser revascularization: A chance for the «inoperable» patient. Eur J Cardiothorac Surg. 1997; 11: 888–894.

10. Lipsic E, Schoemaker RG, van der Meer P et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 2006 Dec 5; 48 (11): 2161–2167.

11. Brunner S, Winogradov J, Huber BC et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J. 2009 Feb; 23 (2): 351–361. doi: 10.1096/fj.08-109462.

12. Ward MR, Stewart DJ.Erythropoietin and mesenchymal stromal cells in angiogenesis and myocardial regeneration: one plus one equals three. Cardiovasc Res. 2008 Aug 1; 79 (3): 357–359. doi: 10.1093/cvr/cvn153.

13. Zhang DG1, Zhang FM, Zhang YQ et al. Erythropoietin enhances the therapy potency of autologous bone marrow stromal cells in a rat heart infarction model via phosphatidylinositol-3-kinase/Akt pathway]. Cardiology. 2007; 108 (4): 228–236.

14. Wang JA, Xie XJ, He H, Sun Y, Jiang J et al.A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Feb; 34 (2): 107–110.

15. Jan van Ramshorst, Saskia LMA Beeres, Sander F. Rodrigo, Petra Dibbets­Schneider et al. Effect of intramyocardial bone marrow-derived mononuclear cell injection on cardiac sympathetic innervation in patients with chronic myocardial ischemia. The International Journal of Cardiovascular Imaging. 2014 March; 30, Issue 3: 583– 589.

16. Гичкун ОЕ, Ярошенко ЕБ, Шевченко АО. Трансплантация аутологичных гемопоэтических стволовых клеток пациентам с рассеянным склерозом. Весці Нацыянальнай акадэміі навук Беларусі. Серыя медыцынскіх навук. 2016; 2: 110–117. Gichkun OE, Yaroshenko EB, Shevchenko AO. Transplantaciya autologichnyh gemopoehticheskih stvolovyh kletok pacientam s rasseyannym sklerozom. Vescі Nacyyanal’naj akadehmіі navuk Belarusі. Seryya medycynskіh navuk. 2016; 2: 110–117.

17. Lykov АР, Poveshchenko OV, Cherniavsky AM et al. Phenotype of bone-marrow mononuclear cells before and after short-time precondition with erythropoietin from patients with ischemic heart failure. Russian Open Medical Journal. 2018; 7, Issue 2. DOI: 10.15275/rusomj.2018.0202.

18. Copland IB, Jolicoeur EM, Gillis MA, Cuerquis J, Eliopoulos N, Annabi B, Calderone A et al. Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res. 2008 Aug 1; 79 (3): 405–415. doi: 10.1093/cvr/cvn090.